Articles On Neuren Pharmaceuticals (ASX:NEU)

On Thursday the Australian sharemarket’s benchmark S&P/ASX 200 Index (ASX: XJO) fell 8.4 points, or 0.1 per cent, to 8550.8, with seven out of 11 sectors closing down. The broader All Ordinaries Index (ASX: XAO) slid 6.3 points, to 8773...

Highlights Xero slides on news of a major acquisition, weighing on tech Neuren Pharmaceuticals rises following US patent approval DroneShield and Pointsbet attract interest on contract and M&A news Australian share...

Highlights Xero weakens after confirming acquisition of US-based payments firm Melio Neuren Pharmaceuticals climbs on a new US patent approval Broader ASX 200 index trends lower with mixed sector performances The Austr...

Neuren Pharma (ASX:NEU) has seen its shares jump over +11% as the company wins a patent to treat Pitt Hopkins Syndrome (PTHS) with its drug NNZ-2591. Listen to the HotCopper podcast for in-depth discussions and insights on all the bigges...

The S&P/ASX 200 Index (ASX: XJO) is out of form on Thursday and trading lower. At the time of writing, the benchmark index is down 0.2% to 8,540.7 points. Four ASX shares that are not letting that hold them back are listed below. Here's...

The market may be having a subdued start to the day but that hasn't stopped two ASX healthcare stocks from racing higher. Let's see why investors are bidding them higher today: Neuren Pharmaceuticals Ltd (ASX: NEU) The Neuren share price i...

UBS reckons healthcare will fare better than any other ASX sector Bell Potter says Monash IVF has fertile recovery prospects Telix wins FDA usage expansion for prostate cancer imaging     Financial giant UBS has declared that enough is e...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin Weekly update on stockbroker recommendation, target price, and earnings forecast cha...

REA Group Ltd (ASX: REA) shares are down 1.43% on Thursday to $233 while the S&P/ASX 200 Index (ASX: XJO) is down 0.12%. Top broker Macquarie recently released a note about Australian residential listings volumes. The note inclu...

There are a total of 200 shares to choose from on the ASX 200 index. Some are buys, some are holds, and some are best avoided. Knowing the difference between which ones are buys and sells is easier said than done, but thankfully there are b...

Many of Australia's top brokers have been busy adjusting their financial models and recommendations again. This has led to the release of a number of broker notes this week. Three ASX shares that brokers have named as buys this week are lis...

Reece Ltd (ASX: REH) shares have been a reliable investment over the past decade. Despite recent wobbles, during this time, the plumbing parts company has quietly delivered an average total return of approximately 10.2% per annum. This mean...

Today, Macquarie initiated coverage on Neuren Pharmaceuticals Ltd (ASX: NEU) shares, tipping significant upside. Neuren Pharmaceuticals has developed DAYBUE (trofinetide), for which Acadia Pharmaceuticals has a worldwide exclusive distr...

Highlights Karoon Energy and Woodside Energy show strong momentum in the energy sector Clarity Pharmaceuticals and Neuren Pharmaceuticals decline amid sectoral rotation Travel, health care, and tech face downward pressure ac...

Highlights ASX 200 advances, led by strength in financials, technology, and retail Tech stocks like NXT, WTC, and XRO post notable gains Gold stocks retreat, with EVN and NEM facing pressure The S&P/ASX 200 Index r...

MND strips voice and movement from thousands Big Freeze and Neale Daniher lead the national fight Control Bionics tech gives the silent a voice   There’s a reason it’s called the Beast. Motor Neurone Disease (MND) creeps in quietly and sl...

The S&P/ASX 200 Health Care Index rose 1.59% in May but remains worst performing sector YTD down 5.65% Morgans healthcare analyst Iain Wilkie said US President Donald Trump’s trade and health policies continue to impact sector Lumos up...

Nyrada is focused on a particular ion pathway to tackle disorders including stroke and traumatic brain injury Preclinical work has shown a significant reduction in secondary brain injury and cardiac damage CEO James Bonnar spent 15 years a...

ASX health stocks up 1.2% over past five days while the broader market is up 0.8%  HealthCo REIT agrees to short-term partial rent deferral with troubled Healthscope and its receivers New-Zealand-based soft-tissue repair company Aroa Biosu...

AI is reshaping microbiology in the labs Big Pharma taps Clever Culture’s APAS system Here are ASX biotechs with global health deals    Step into a modern microbiology lab today and you might notice something’s different. The culture plat...

Highlights ASX 200 reaches new short-term high, led by Energy and Information Technology sectors Capstone Copper Corp. (ASX:CSC) and Clarity Pharmaceuticals Ltd (ASX:CU6) among top midday performers Paladin Energy Ltd (ASX:P...

Highlights ASX 200 posts slight gain in a subdued and low-volume session Energy sector gains on project approval, pharmaceuticals lift on US trade ruling Stocks with US and China exposure see limited movement despite tariff...

Highlights: Gains in Wisetech Global, Lovisa, and the major banks lifted the ASX 200 Technology, Energy, and Consumer Discretionary sectors showed strength throughout the session Gold stocks saw notable declines, with Evolut...

It was a very positive session for the S&P/ASX 200 Index (ASX: XJO) and many ASX shares this Tuesday, with the markets throwing off the caution that they started the week with yesterday. After a sha...

Highlights: Lithium sector slides after China’s EV price reductions by BYD InFocus Group surges after securing iGaming technology partnership Telstra outlines its long-term digital infrastructure and emissions plan The...

 Optiscan’s telepathology streaming software enables surgeons to have secure real-time access to pathologists – no matter where they are in the world 4D Medical’s device probes the lung’s innards without the nasties Painchek signs a US dis...

The S&P/ASX 200 Index (ASX: XJO) is on course to record a small gain. In afternoon trade, the benchmark index is up slightly to 8,366.6 points. Four ASX shares that are rising more than most today are listed below. Here's why they are c...

Australia has become well-known for its paediatric drug discovery with several life-altering treatments CSL is a global leader in developing therapies for children with haemophilia and other serious blood disorders Neurotech International...

Highlights Neuren Pharmaceuticals Limited (NEU) is listed under the ASX Healthcare index. The company experienced a recent share price increase but remains down over a twelve-month period. Price-to-earnings ratio reflects ea...

Highlights: ASX healthcare stocks edge ahead of the broader market with key innovations and updates PolyNovo (ASX:PNV) unveils promising NovoSorb developments in diabetes research Neuren (ASX:NEU), Microba (ASX:MAP), and Ram...

ASX health stocks up 2.1% over past week, while the broader market is up 2%  President Donald Trump signs executive order to cut US drug prices under ‘most favored nation’ policy PolyNovo has a breakthrough with its NovoSorb technology in...

The S&P/ASX 200 Index (ASX: XJO) snatched a victory from the jaws of defeat this Wednesday. After sinking into red territory for most of today's session, the ASX 200 recovered in the nick of time t...

Highlights Core Lithium’s stock experiences strongest daily movement since a previous multi-year high Finniss Project study outlines lowered operational and capital costs with increased production ASX 200 continues upward tr...

US President Donald Trump has signed an executive order aimed at reducing drug costs for Americans, by up to 80% immediately. The move immediately hit Australia's pharmaceutical industry as 3 ASX pharmaceutical stocks crashed up to 10% s...

 Investors with a short position in wound care house Polynovo face a nervous wait Oz drug stocks partly recover after swooning yesterday on Trump drug-pricing edict Wellnex Life rediscovers its sales mojo, while Elinixol Wellness goes to t...

Highlights Mineral Resources (MIN) observed increased market activity amid global trade updates. Elixir Energy (EXR) advanced following a new strategic direction led by recent leadership changes. Biotechnology stocks, includ...

Some of the ASX’s best-known pharmaceutical companies – including Neuren, Telix and Clarity – have reported losses on Monday, after Donald Trump announced a plan to cut prescriptions drug prices by up to 80% via an executive order. The i...

Highlights Energy and mining stocks helped lift the ASX200 on Monday. Trade optimism between the US and China boosted commodity sentiment. Macquarie and South32 were notable movers in corporate news. The Australian share market ki...

Highlights Mineral Resources Ltd (ASX:MIN) drew attention amid governance-related news and stock price action South32 Ltd (ASX:S32) reported executive leadership transition affecting market sentiment Neuren Pharmaceuticals L...

Highlights ASX pharmaceutical stocks saw notable declines following U.S. policy comments. Trump's proposal aims to drastically cut U.S. prescription drug prices. Companies with U.S.-based pipelines or approvals felt the immediate mark...

Highlights  ASX200 sees modest gains amid global optimism  Energy and mining stocks climb on stronger commodity prices  Goodman Group and BHP lead early momentum  The Australian share market opened the week on a positive note, wit...

The ASX200 has been up 0.32% at around 8,257 points. Mineral Resources Ltd (ASX:MIN) has been well-watched on HotCopper today, after rising 5.65% despite news that superannuation fund HESTA has sold its remaining stake in the company, ci...

Highlights  ASX200 rises on positive US-China trade sentiment  BHP and Santos among top performing resource stocks  Copper discovery, iron ore jump support mining sector  The Australian sharemarket opened on a positive note, buoye...

It was a positive end to the trading week for the S&P/ASX 200 Index (ASX: XJO) and many ASX shares this Friday. A third day of gains in a row for the ASX 200 saw it close at 8,231.2 points today. T...

Highlights: ANZ Group provides insights into first-half earnings, with a focus on capital stability and strategic de-risking. S&P/ASX 200 remains flat at noon with fluctuations across various sectors. Unusual volume obse...

Highlights Neuren Pharmaceuticals (NEU) reported strong sales figures in the biotech sector. Pointerra (3DP) advanced in the tech space with a US Army contract. Locksley Resources (LKY) moved forward with drilling approvals...

The ASX200 has been up 0.2% at around 8,195 points. Neuren Pharmaceuticals (ASX:NEU) has been the most watched on HotCopper so far today, after reporting Q1 FY25 sales of its DAYBUE product increased by 11% to US$84.6 million over the co...

Neuren says the number of patients discontinuing its Rett syndrome drug has fallen by two-thirds over the last year LTR Pharma launches a secondary program for swallowing disorders Telix targets throat – and other – cancers Neuren Pharmac...

The S&P/ASX 200 Index (ASX: XJO) enjoyed a strong finish this Friday in what has been a strong week for the share market. By the time the closing bell rang, the ASX 200 had jumped up a healthy 1.13...

Highlights Several ASX 200 directors made notable share purchases, including from Neuren Pharmaceuticals, BHP, GQG Partners, and Viva Energy Group. BHP's directors acquired additional shares amid market fluctuations, while GQG's...